☰

Abhijeet J. Bhanegaonkar, Ph.D. - Publications

Affiliations: 
2012 West Virginia University, Morgantown, WV, United States 
Area:
Pharmacy
Tree Info Similar researchers PubMed Report error

6/43 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Bhanegaonkar A, Madhavan SS, Khanna R, Remick SC. Declining mammography screening in a state Medicaid Fee-for-Service program: 1999-2008. Journal of Women's Health (2002). 21: 821-9. PMID 22568434 DOI: 10.1089/Jwh.2011.2748  0.581
2011 Khanna R, Madhavan SS, Bhanegaonkar A, Remick SC. Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. Journal of Women's Health (2002). 20: 739-47. PMID 21417935 DOI: 10.1089/Jwh.2010.2298  0.593
2011 Bhanegaonkar A, Madhavan S, Pawar GV, Rajagopalan K, Langlois J. Pnd50 Understanding Health Related Quality Of Life Changes And Issues Related To Disease Modifying Drugs Among Multiple Sclerosis Patients: A Qualitative Study Value in Health. 14. DOI: 10.1016/J.Jval.2011.02.1160  0.349
2009 Khanna R, Bhanegaonkar A, Colsher P, Madhavan SS, Halverson J. Breast cancer screening, incidence, and mortality in West Virginia. The West Virginia Medical Journal. 105: 24-32. PMID 19999262  0.573
2009 Khanna R, Madhavan S, Bhanegaonkar A. Pcn109 Breast Cancer Prevalence And Health Care Utilization And Cost Trends Among Fee-For-Service Female Recipients In A State Medicaid Program Value in Health. 12. DOI: 10.1016/S1098-3015(10)73344-1  0.568
2009 Bhanegaonkar A, Khanna R, Madhavan S. Pcn103 Screening Mammography Trends Among Women In A Fee-For-Service Medicaid Population Value in Health. 12. DOI: 10.1016/S1098-3015(10)73339-8  0.549
Low-probability matches (unlikely to be authored by this person)
2021 Bilen M, Xi A, Schroeder A, Kim R, Liu F, Wong A, Peng J, Jones B, Robinson S, Bhanegaonkar A. PCN241 Treatment Pattern and Healthcare Resource Utilization (HRU) in Patients with Metastatic Urothelial Carcinoma (MUC) Among Medicare Fee-for-Service (FFS) Beneficiaries: Results from IMPACT UC Value in Health. 24: S65. DOI: 10.1016/J.JVAL.2021.04.331  0.234
2012 Jones DL, Bhanegaonkar AJ, Billings AA, Kriska AM, Irrgang JJ, Crossett LS, Kwoh CK. Differences between actual and expected leisure activities after total knee arthroplasty for osteoarthritis. The Journal of Arthroplasty. 27: 1289-96. PMID 22480521 DOI: 10.1016/J.Arth.2011.10.030  0.229
2006 Wu T, Bhanegaonkar AJ, Flowers JW. Blood concentrations of selected volatile organic compounds and neurobehavioral performance in a population-based sample. Archives of Environmental & Occupational Health. 61: 17-25. PMID 17503617 DOI: 10.3200/Aeoh.61.1.17-25  0.191
2007 Jones DL, Bhanegaonkar A, Kriska AM, Irrgang JJ, Crossett LS, Kwoh CK. Physical Activity Expectations Within Two Cohorts With Knee Osteoarthritis Medicine & Science in Sports & Exercise. 39: S230. DOI: 10.1249/01.Mss.0000273872.57084.3D  0.189
2019 Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. Clinicoeconomics and Outcomes Research : Ceor. 11: 659-672. PMID 31807039 DOI: 10.2147/CEOR.S215069  0.187
2011 Canafax DM, Bhanegaonkar A, Bharmal M, Calloway M. Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. Bmc Neurology. 11: 48. PMID 21527006 DOI: 10.1186/1471-2377-11-48  0.174
2018 Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar K, Kearney M. PCN339 - SPEAR-BLADDER (STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER): TIMING OF TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER IN THE COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES Value in Health. 21: S72. DOI: 10.1016/j.jval.2018.09.421  0.163
2019 Bhanegaonkar A, Kim R, Pandya S, Krulewicz S, Wang L, Pennock G, Phatak H. TP1 REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH METASTATIC UROTHELIAL CANCER RECEIVING SECOND-LINE THERAPY IN THE US VETERAN POPULATION Value in Health. 22: S390. DOI: 10.1016/J.JVAL.2019.04.1905  0.162
2014 Bhanegaonkar AJ, Horodniceanu EG, Gonzalez RRH, Canlas Dizon MV, Detzel P, Erdogan-Ciftci E, Verheggen B, Botteman MF. Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants. Value in Health Regional Issues. 3: 124-135. PMID 29702918 DOI: 10.1016/j.vhri.2014.04.001  0.142
2020 Doshi GK, Bhanegaonkar A, Kearney M, Bharmal M, Cislo P, Kim R, Boyd M, Aguilar KM, Phatak H. Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR). Clinicoeconomics and Outcomes Research : Ceor. 12: 645-656. PMID 33192078 DOI: 10.2147/CEOR.S264942  0.138
2019 Kangethe A, Polson M, Speicher LC, Zheng Y, Bhanegaonkar A, Krulewicz S, Kim R. Exploratory analysis of the cost of episodes of care in metastatic renal cell carcinoma in the United States. Journal of Clinical Oncology. 37: 55-55. DOI: 10.1200/jco.2019.37.27_suppl.55  0.134
2014 Bhanegaonkar AJ, Horodniceanu EG, Gonzalez RRH, Canlas Dizon MV, Detzel P, Erdogan-Ciftci E, Verheggen B, Botteman MF. Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Value in Health Regional Issues. 3: 124-135. DOI: 10.1016/j.vhri.2014.04.001  0.129
2019 Bhanegaonkar A, Kim R, Pandya S, Wang L, Krulewicz S, Pennock G, Phatak H. PCN314 REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING FIRST-LINE THERAPY IN THE UNITED STATES VETERAN POPULATION Value in Health. 22: S116. DOI: 10.1016/J.JVAL.2019.04.432  0.118
2018 Doshi G, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar K, Kim R, Cislo P, Kearney M. Patient Characteristics And Treatment Patterns From Spear-Bladder: Study Informing Treatment Pathway Decision In Bladder Cancer Value in Health. 21: S49. DOI: 10.1016/j.jval.2018.04.290  0.108
2019 Botteman MF, Munasir Z, Sulistomo AW, Horodniceanu EG, Bhanegaonkar AJ, Ji X, Tang WY, Basrowi RW, Detzel P. Economic value of atopic dermatitis prevention via partially-hydrolyzed whey-based infant formula (PHF-W) use in high-risk, non-exclusively breastfed, Indonesian urban infants: results of a cost-effectiveness model World Nutrition Journal. 2: 43. DOI: 10.25220/WNJ.V02.I2.0008  0.1
2020 Bhanegaonkar A, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S, Kasturi V, Cowey CL. Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC). Journal of Clinical Oncology. 38: 269-269. DOI: 10.1200/JCO.2020.38.29_SUPPL.269  0.096
2021 Hutson TE, Liu FX, Dieyi C, Kim R, Krulewicz S, Kasturi V, Bhanegaonkar A. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis. Journal of Managed Care & Specialty Pharmacy. 1-11. PMID 34165322 DOI: 10.18553/jmcp.2021.20569  0.095
2023 Bilen MA, Robinson SB, Schroeder A, Peng J, Kim R, Liu FX, Bhanegaonkar A. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study). The Oncologist. PMID 37432283 DOI: 10.1093/oncolo/oyad174  0.091
2018 Doshi GK, Bhanegaonkar A, Bharmal M, Phatak H, Boyd M, Aguilar KM, Kearney M. SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US. Journal of Clinical Oncology. 36: 4544-4544. DOI: 10.1200/JCO.2018.36.15_SUPPL.4544  0.089
2019 Kim R, Bhanegaonkar A, Krulewicz S, Polson M, Kangethe A. PCN282 EXPLORATORY ANALYSIS OF ADHERENCE TO ANTICANCER THERAPIES IN METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES (US) Value in Health. 22: S109. DOI: 10.1016/J.JVAL.2019.04.401  0.079
2014 Bhanegaonkar A, Lee BW, Shek Pei Chi L, Van Bever H, Horodniceanu EG, Ji X, Detzel P, Botteman MF. Modeling the Cost-Effectiveness of 100% Whey-Based Partially Hydrolyzed Versus. Cow's Milk Infant Formula in the Prevention of Atopic Dermatitis in Singapore. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A779. PMID 27202886 DOI: 10.1016/j.jval.2014.08.364  0.075
2020 Cowey C, Liu F, Kim R, Boyd M, Fulcher N, Krulewicz S, Smith J, Bhanegaonkar A. 1090P Real-world (RW) clinical outcomes in patients (pts) with locally advanced (LA) or metastatic Merkel cell carcinoma (mMCC) treated in United States (US) oncology clinical practices: Results from SPEAR-Merkel Annals of Oncology. 31: S739-S740. DOI: 10.1016/j.annonc.2020.08.1214  0.074
2014 Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. Aids Research and Human Retroviruses. 30: 753-68. PMID 24925216 DOI: 10.1089/Aid.2013.0262  0.074
2021 Bhanegaonkar A, Pandya S, Zheng Y, Kim R, Krulewicz S, Kasturi V, Phatak H. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. Advances in Therapy. 38: 2644-2661. PMID 33866526 DOI: 10.1007/s12325-021-01657-2  0.071
2019 Doshi GK, Kearney M, Bharmal M, Phatak H, Boyd M, Aguilar K, Kim R, Bhanegaonkar A. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States. Journal of Clinical Oncology. 37: 453-453. DOI: 10.1200/JCO.2019.37.7_SUPPL.453  0.071
2020 Hutson TE, Liu FX, Pandya S, Dieyi C, Kim R, Krulewicz S, Kasturi V, Bhanegaonkar A. Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study. Journal of Clinical Oncology. 38: e17079-e17079. DOI: 10.1200/jco.2020.38.15_suppl.e17079  0.07
2021 Cowey CL, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S, Kasturi V, Bhanegaonkar A. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel. Future Oncology (London, England). PMID 33709776 DOI: 10.2217/fon-2020-1250  0.066
2021 Bhanegaonkar A, Liu FX, Boyd M, Fulcher N, Kim R, Krulewicz S, Smith J, Cowey CL. Real-World Clinical Outcomes in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in US Oncology Clinical Practices: Results From SPEAR-Merkel. The Oncologist. PMID 34101298 DOI: 10.1002/onco.13845  0.056
2020 Bhanegaonkar A, Gauthier G, Kim R, Vekeman F, Dea K, Robitaille M, Moyneur É, Liu F. PCN341 REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) Value in Health. 23: S84. DOI: 10.1016/j.jval.2020.04.1799  0.056
2017 Botteman MF, Bhanegaonkar AJ, Horodniceanu EG, Ji X, Lee BW, Shek LP, Van Bever HP, Detzel P. Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore. Singapore Medical Journal. PMID 29214323 DOI: 10.11622/smedj.2017113  0.052
2023 Gupta S, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Su C, Thakkar S, Mackie DS, Devgan G, Katzenstein HM, Liu FX. Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study. The Oncologist. PMID 37846191 DOI: 10.1093/oncolo/oyad267  0.047
2015 Bhanegaonkar A, Horodniceanu EG, Ji X, Detzel P, Boguniewicz M, Chamlin S, Lake A, Czerkies LA, Botteman MF, Saavedra JM. Economic Burden of Atopic Dermatitis in High-Risk Infants Receiving Cow's Milk or Partially Hydrolyzed 100% Whey-Based Formula. The Journal of Pediatrics. 166: 1145-1151.e3. PMID 25919724 DOI: 10.1016/j.jpeds.2015.02.017  0.046
2015 Bhanegaonkar AJ, Horodniceanu EG, Abdul Latiff AH, Woodhull S, Khoo PC, Detzel P, Ji X, Botteman MF. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. Asia Pacific Allergy. 5: 84-97. PMID 25938073 DOI: 10.5415/apallergy.2015.5.2.84  0.033
2014 Bhanegaonkar A, Qin L, Horodniceanu EH, Ji X, Detzel P, Botteman M. Economic Burden of Pediatric Atopic Dermatitis in Asia-Pacific: A Review of the Literature. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A778. PMID 27202881 DOI: 10.1016/j.jval.2014.08.358  0.032
2020 Bhanegaonkar A, Pandya S, Kim R, Zheng Y, Dieyi C, Krulewicz S, Kasturi V, Liu F, Hutson T. PCN114 IMPACT RCC REAL-WORLD STUDY: ECONOMIC IMPACT OF EARLY PROGRESSION AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS IN FIRST-LINE SETTING Value in Health. 23: S42-S43. DOI: 10.1016/j.jval.2020.04.1605  0.03
2014 Bhanegaonkar A, Horodniceanu EG, Ji X, Detzel P, Botteman MF. Burden of Atopic Dermatitis in Indonesia, Malaysia, and Singapore: Estimates from a Mathematical Model. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A778. PMID 27202882 DOI: 10.1016/j.jval.2014.08.359  0.026
2005 Bhanegaonkar A, Flowers J, Hogan M, Wu T. 184: Exposure to Volatile Organic Compounds and Neurobehavioral Effect American Journal of Epidemiology. 161: S46-S46. DOI: 10.1093/aje/161.supplement_1.s46c  0.018
Hide low-probability matches.